Despite all the hype surrounding bryostatin, I have significant doubts. It seeks maximum synaptogenesis by strongly increasing levels of growth factors. I've been informed by a neurologist that unregulated synaptogenesis has a downside, increased incidence of seizures and behavioral/psyche issues for people that have Alzheimers. Long term, I believe bryostatin will produce a lot of side effects and adverse events in people with Alzheimer's. The track record for drugs that increase growth factors is not good. Bryostatin does not at all address/correct mitochondrial dysfunction. Many Alzheimers experts describe Alzheimers as a "mitochondrial dysfunction disease". The short term results for bryostatin I expect to be good. However, I see this drug as neurorestorative but not neuroprotective, so I don't see it as a long term solution for treating Alzheimers. The sigma 1 drugs show correction of mitochondrial dysfunction (neuroprotection) and also boost synaptogenesis (neurorestoration), tho their synaptogenesis is more measured and regulated for when the neurons need it. Sigma 1 drugs stimulate PKC via M1 receptor stimulation and via releasing calcium from IP3 channels as needed. Sigma drugs treat microglial cells and oligodendrocytes, not just neurons. Not aware that bryostatin does this. That is crucial b/c those brain cells are effected by Alzheimers. Bryostatin given for the treatment of Alzheimers reminds me of anabolic steroids, such as testesterone. In the short term, they work great, you see a huge response intitially. However, long term, problems arise (side effects and adverse events). 80's NFL football player Lyle Alzedo is an example of long term use of steroids. Neurotrope is wise to keep their trials to the unheard of length of just 3 months, which I've never seen before in a Ph 2b or Ph 3 Alzheimers trial. It is incorrect to compare Anavex 273's Ph 2a trial to Neurotrope's Ph 2b trial for bryostatin. There is a difference between Ph 2a and Ph 2b. Different end points. Neurotrope did run a Ph 2a trial for bryostatin, but I can't find the full top line results for that trial. Weird. They admined ONE DOSE of the drug and that was the extent of their Ph 2a to "prove" safety of the drug in Alzheimers patients Lol.
Was it bryostatin's Ph 2b or Ph 3 or both that were initially planned to be 6 months but then were shortened to just 3 months? That is a red flag imo. Are the Ph 2a patients still on the drug? If not, why wasn't this option given to the patients if the drug is so great? Are the compassionate use patients all on the drug still? If not, why not, if the drug is so great long term? I heard the Ph 2b patients will be tracked for one month after the trial ends but those patients won't be able to continue on the drug until AFTER the drug is FDA approved. Is that correct? If so, that is strange and concerning. Is Neurotrope afraid if they continue on the drug side effects may pop up which might interfere with the drug gaining FDA approval?
